Idhifa

Overview

enasidenib

IDH2 inhibitor

• CYP1A2 inhibitor, strong
• CYP2C19 inhibitor, weak
• CYP2D6 inhibitor, weak
• BCRP inhibitor
• OATP1B1 inhibitor, moderate
• OATP1B3 inhibitor, moderate
• P-gp inhibitor, weak
• CYP3A4 inducer, weak

Contraindicated

• colchicine
Idhifa (enasidenib)

+

colchicine

1 interaction

Contraindicated

enasidenib + colchicine

CV RISK REDUCTION: consider monitoring CK, myopathy s/sx; GOUT OR FMF: contraindicated in pts w/ renal or hepatic impairment; otherwise, consider decr. colchicine dose during and x14 days after enasidenib use: combo may incr. colchicine levels, risk of myopathy, rhabdomyolysis, other life-threatening toxicity (P-gp-mediated transport inhibited)

• elagolix
Idhifa (enasidenib)

+

elagolix

1 interaction

Contraindicated

enasidenib + elagolix

contraindicated: combo may incr. elagolix levels, risk of adverse effects (hepatic transport inhibited)

• eliglustat
Idhifa (enasidenib)

+

eliglustat

1 interaction

Contraindicated

enasidenib + eliglustat

CYP2D6 EM: if Child-Pugh Class A, consider alternative or eliglustat dose adjustment; otherwise, consider alternative or monitor ECG; CYP2D6 IM: contraindicated if also combined w/ strong CYP3A4 inhibitor; avoid combo if also combined w/ moderate CYP3A4 inhibitor; otherwise, consider alternative or monitor ECG; CYP2D6 PM: contraindicated if also combined w/ strong CYP3A4 inhibitor; avoid combo if also combined w/ weak or moderate CYP3A4 inhibitor; otherwise, consider alternative or monitor ECG: combo may incr. or decr. eliglustat levels, incr. risk of PR or QT prolongation, cardiac arrhythmias, other adverse effects or decr. efficacy (hepatic metabolism altered)

• fezolinetant
Idhifa (enasidenib)

+

fezolinetant

1 interaction

Contraindicated

enasidenib + fezolinetant

contraindicated: combo may incr. fezolinetant levels, risk of adverse effects (hepatic metabolism inhibited)

• grazoprevir
Idhifa (enasidenib)

+

grazoprevir

1 interaction

Contraindicated

enasidenib + grazoprevir

contraindicated: combo may incr. or decr. grazoprevir levels, incr. risk of adverse effects or decr. efficacy (hepatic transport inhibited, hepatic metabolism induced)

• ranolazine
Idhifa (enasidenib)

+

ranolazine

1 interaction

Contraindicated

enasidenib + ranolazine

contraindicated: combo may incr. or decr. ranolazine levels, incr. risk of QT prolongation, cardiac arrhythmias, other adverse effects or decr. efficacy (P-gp-mediated transport inhibited, hepatic metabolism induced)

• thioridazine
Idhifa (enasidenib)

+

thioridazine

1 interaction

Contraindicated

enasidenib + thioridazine

contraindicated: combo may incr. thioridazine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• tizanidine
Idhifa (enasidenib)

+

tizanidine

1 interaction

Contraindicated

enasidenib + tizanidine

contraindicated: combo may incr. tizanidine levels, risk of hypotension (including orthostasis, syncope), bradycardia, CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

Avoid/Use Alternative

• alosetron
Idhifa (enasidenib)

+

alosetron

1 interaction

Avoid/Use Alternative

enasidenib + alosetron

avoid combo: combo may incr. alosetron levels, risk of adverse effects (hepatic metabolism inhibited)

• alpelisib
Idhifa (enasidenib)

+

alpelisib

1 interaction

Avoid/Use Alternative

enasidenib + alpelisib

use alternative: combo may incr. alpelisib levels, risk of adverse effects (BCRP-mediated transport possibly inhibited)

• apixaban
Idhifa (enasidenib)

+

apixaban

1 interaction

Avoid/Use Alternative

enasidenib + apixaban

ADULT PTS: monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban 5mg bid or 10 mg bid dose by 50% or avoid combo if already on 2.5 mg bid; PEDS PTS: monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• atazanavir
Idhifa (enasidenib)

+

atazanavir

1 interaction

Avoid/Use Alternative

enasidenib + atazanavir

avoid combo: combo may decr. atazanavir levels, efficacy (hepatic metabolism induced)

• atrasentan
Idhifa (enasidenib)

+

atrasentan

1 interaction

Avoid/Use Alternative

enasidenib + atrasentan

avoid combo: combo may incr. atrasentan levels, risk of adverse effects (hepatic transport inhibited)

• bendamustine
Idhifa (enasidenib)

+

bendamustine

1 interaction

Avoid/Use Alternative

enasidenib + bendamustine

consider alternatives: combo may incr. bendamustine levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• brincidofovir
Idhifa (enasidenib)

+

brincidofovir

1 interaction

Avoid/Use Alternative

enasidenib + brincidofovir

consider alternative or monitor LFTs, GI toxicity sx; give brincidofovir at least 3h before enasidenib: combo may incr. brincidofovir levels, risk of hepatotoxicity, GI toxicity, other adverse effects (hepatic transport inhibited)

• cladribine oral
Idhifa (enasidenib)

+

cladribine oral

1 interaction

Avoid/Use Alternative

enasidenib + cladribine oral

use alternative or monitor CBC: combo may incr. cladribine levels, risk of serious infection, myelosuppression, other adverse effects (gut BCRP-mediated transport inhibited)

• codeine
Idhifa (enasidenib)

+

codeine

1 interaction

Avoid/Use Alternative

enasidenib + codeine

use alternative or monitor resp. rate, withdrawal sx: combo may incr. codeine levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects; may decr. codeine and active metabolite morphine levels, efficacy (hepatic metabolism altered, decr. conversion to morphine)

• dabigatran
Idhifa (enasidenib)

+

dabigatran

1 interaction

Avoid/Use Alternative

enasidenib + dabigatran

ATRIAL FIBRILLATION: avoid combo if CrCl <30 mL/min; OTHER INDICATIONS: avoid combo if CrCl <50 mL/min; if dabigatran use for DVT/PE prophylaxis post-hip replacement and CrCl >50 mL/min, consider separating admin. at least 2h apart: combo may incr. dabigatran levels, risk of bleeding (including life-threatening), other adverse effects (P-gp-mediated transport inhibited)

• desogestrel (contraceptive)
Idhifa (enasidenib)

+

desogestrel (contraceptive)

1 interaction

Avoid/Use Alternative

enasidenib + desogestrel (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after enasidenib tx: combo may decr. desogestrel levels, contraceptive efficacy (hepatic metabolism induced)

• dienogest (contraceptive)
Idhifa (enasidenib)

+

dienogest (contraceptive)

1 interaction

Avoid/Use Alternative

enasidenib + dienogest (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after enasidenib tx: combo may decr. dienogest levels, contraceptive efficacy (hepatic metabolism induced)

• dihydrocodeine
Idhifa (enasidenib)

+

dihydrocodeine

1 interaction

Avoid/Use Alternative

enasidenib + dihydrocodeine

use alternative or monitor resp. rate, withdrawal sx: combo may incr. dihydrocodeine levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects; may decr. active metabolite dihydromorphine levels, efficacy (hepatic metabolism inhibited, decr. conversion to dihydromorphine)

• dolutegravir
Idhifa (enasidenib)

+

dolutegravir

1 interaction

Avoid/Use Alternative

enasidenib + dolutegravir

avoid combo: combo may decr. dolutegravir levels, efficacy (hepatic metabolism induced)

• drospirenone (contraceptive)
Idhifa (enasidenib)

+

drospirenone (contraceptive)

1 interaction

Avoid/Use Alternative

enasidenib + drospirenone (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after enasidenib tx: combo may decr. drospirenone levels, contraceptive efficacy (hepatic metabolism induced)

• duloxetine
Idhifa (enasidenib)

+

duloxetine

1 interaction

Avoid/Use Alternative

enasidenib + duloxetine

avoid combo: combo may incr. duloxetine levels, risk of adverse effects (hepatic metabolism inhibited)

• ensartinib
Idhifa (enasidenib)

+

ensartinib

1 interaction

Avoid/Use Alternative

enasidenib + ensartinib

avoid combo: combo may incr. ensartinib levels, risk of bradycardia, hyperglycemia, other adverse effects (P-gp-mediated transport possibly inhibited)

• erlotinib
Idhifa (enasidenib)

+

erlotinib

1 interaction

Avoid/Use Alternative

enasidenib + erlotinib

if also combined w/ strong CYP3A4 inhibitor, use alternative or consider erlotinib dose adjustment; otherwise, caution advised: combo may incr. or decr. erlotinib levels, incr. risk of adverse effects or decr. efficacy (hepatic metabolism altered)

• estradiol (contraceptive)
Idhifa (enasidenib)

+

estradiol (contraceptive)

1 interaction

Avoid/Use Alternative

enasidenib + estradiol (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after enasidenib tx: combo may decr. estradiol levels, contraceptive efficacy (hepatic metabolism induced)

• ethinyl estradiol (contraceptive)
Idhifa (enasidenib)

+

ethinyl estradiol (contraceptive)

1 interaction

Avoid/Use Alternative

enasidenib + ethinyl estradiol (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after enasidenib tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced)

• ethynodiol (contraceptive)
Idhifa (enasidenib)

+

ethynodiol (contraceptive)

1 interaction

Avoid/Use Alternative

enasidenib + ethynodiol (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after enasidenib tx: combo may decr. ethynodiol and active metabolite levels, contraceptive efficacy (hepatic metabolism induced)

• etonogestrel (contraceptive)
Idhifa (enasidenib)

+

etonogestrel (contraceptive)

1 interaction

Avoid/Use Alternative

enasidenib + etonogestrel (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after enasidenib tx: combo may decr. etonogestrel levels, contraceptive efficacy (hepatic metabolism induced)

• fentanyl
Idhifa (enasidenib)

+

fentanyl

1 interaction

Avoid/Use Alternative

enasidenib + fentanyl

use alternative or monitor withdrawal sx: combo may decr. fentanyl levels, efficacy (hepatic metabolism induced)

• fosamprenavir
Idhifa (enasidenib)

+

fosamprenavir

1 interaction

Avoid/Use Alternative

enasidenib + fosamprenavir

avoid combo: combo may decr. amprenavir levels, efficacy (hepatic metabolism induced)

• levonorgestrel (contraceptive)
Idhifa (enasidenib)

+

levonorgestrel (contraceptive)

1 interaction

Avoid/Use Alternative

enasidenib + levonorgestrel (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after enasidenib tx: combo may decr. levonorgestrel levels, contraceptive efficacy (hepatic metabolism induced)

• levonorgestrel (post-coital contraceptive)
Idhifa (enasidenib)

+

levonorgestrel (post-coital contraceptive)

1 interaction

Avoid/Use Alternative

enasidenib + levonorgestrel (post-coital contraceptive)

consider alternative: combo may decr. levonorgestrel levels, post-coital contraceptive efficacy (hepatic metabolism induced)

• lopinavir/ritonavir
Idhifa (enasidenib)

+

lopinavir/ ritonavir

1 interaction

Avoid/Use Alternative

enasidenib + lopinavir/ ritonavir

avoid combo: combo may decr. lopinavir/ritonavir levels, efficacy (hepatic metabolism induced)

• lumateperone
Idhifa (enasidenib)

+

lumateperone

1 interaction

Avoid/Use Alternative

enasidenib + lumateperone

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism induced)

• mavacamten
Idhifa (enasidenib)

+

mavacamten

1 interaction

Avoid/Use Alternative

enasidenib + mavacamten

consider alternative or monitor cardiac fxn, incl. LVEF; consider mavacamten dose adjustment: combo may incr. or decr. mavacamten levels, incr. risk of heart failure, other adverse effects or decr. efficacy (hepatic metabolism altered)

• medroxyprogesterone (contraceptive)
Idhifa (enasidenib)

+

medroxyprogesterone (contraceptive)

1 interaction

Avoid/Use Alternative

enasidenib + medroxyprogesterone (contraceptive)

use additional non-hormonal or alternative contraception: combo may decr. medroxyprogesterone levels, contraceptive efficacy (hepatic metabolism induced)

• meperidine
Idhifa (enasidenib)

+

meperidine

1 interaction

Avoid/Use Alternative

enasidenib + meperidine

use alternative or monitor for withdrawal sx: combo may decr. meperidine levels, efficacy; may incr. normeperidine levels, risk of neurotoxicity (hepatic metabolism induced, incr. toxic metabolite formation)

• methadone
Idhifa (enasidenib)

+

methadone

1 interaction

Avoid/Use Alternative

enasidenib + methadone

use alternative or monitor resp. rate, ECG, consider decr. methadone dose: combo may incr. or decr. methadone levels, incr. risk of CNS and resp. depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects or decr. efficacy (hepatic metabolism altered)

• neratinib
Idhifa (enasidenib)

+

neratinib

1 interaction

Avoid/Use Alternative

enasidenib + neratinib

avoid combo if also combined w/ strong-mod CYP3A4 inhibitor; otherwise, caution advised: combo may incr. or decr. neratinib levels, incr. risk of adverse effects or decr. efficacy (P-gp-mediated transport inhibited, hepatic metabolism induced)

• norelgestromin (contraceptive)
Idhifa (enasidenib)

+

norelgestromin (contraceptive)

1 interaction

Avoid/Use Alternative

enasidenib + norelgestromin (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after enasidenib tx: combo may decr. norelgestromin levels, contraceptive efficacy (hepatic metabolism induced)

• norethindrone (contraceptive)
Idhifa (enasidenib)

+

norethindrone (contraceptive)

1 interaction

Avoid/Use Alternative

enasidenib + norethindrone (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after enasidenib tx: combo may decr. norethindrone levels, contraceptive efficacy (hepatic metabolism induced)

• norgestimate (contraceptive)
Idhifa (enasidenib)

+

norgestimate (contraceptive)

1 interaction

Avoid/Use Alternative

enasidenib + norgestimate (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after enasidenib tx: combo may decr. norgestimate and active metabolites levels, contraceptive efficacy (hepatic metabolism induced)

• norgestrel (contraceptive)
Idhifa (enasidenib)

+

norgestrel (contraceptive)

1 interaction

Avoid/Use Alternative

enasidenib + norgestrel (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after enasidenib tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

• oliceridine
Idhifa (enasidenib)

+

oliceridine

1 interaction

Avoid/Use Alternative

enasidenib + oliceridine

use alternative or monitor resp. rate, ECG, withdrawal sx; consider oliceridine dose adjustment: combo may incr. or decr. oliceridine levels, incr. risk of CNS and resp. depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects or decr. efficacy (hepatic metabolism altered)

• oxycodone
Idhifa (enasidenib)

+

oxycodone

1 interaction

Avoid/Use Alternative

enasidenib + oxycodone

use alternative or monitor withdrawal sx: combo may decr. oxycodone levels, efficacy (hepatic metabolism induced)

• pazopanib
Idhifa (enasidenib)

+

pazopanib

1 interaction

Avoid/Use Alternative

enasidenib + pazopanib

avoid combo: combo may incr. pazopanib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (BCRP-mediated transport inhibited)

• pimozide
Idhifa (enasidenib)

+

pimozide

1 interaction

Avoid/Use Alternative

enasidenib + pimozide

use alternative or monitor ECG: combo may incr. pimozide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• pirfenidone
Idhifa (enasidenib)

+

pirfenidone

1 interaction

Avoid/Use Alternative

enasidenib + pirfenidone

avoid combo if also combined w/ mod-strong CYP2C9, CYP2C19, CYP2D6, or CYP2E1 inhibitor; otherwise, consider alternative or decr. pirfenidone dose to 267 mg tid: combo may incr. pirfenidone levels, risk of adverse effects (hepatic metabolism inhibited)

• pomalidomide
Idhifa (enasidenib)

+

pomalidomide

1 interaction

Avoid/Use Alternative

enasidenib + pomalidomide

use alternative or monitor CBC; decr. pomalidomide dose to 2 mg: combo may incr. pomalidomide levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• pralsetinib
Idhifa (enasidenib)

+

pralsetinib

1 interaction

Avoid/Use Alternative

enasidenib + pralsetinib

use alternative or consider monitoring ECG, electrolytes and decr. pralsetinib dose as follows: if on pralsetinib 400 mg qd, decr. to 300 mg qd; if on pralsetinib 400 mg qd and also combined w/ strong CYP3A4 inhibitor: decr. to 200 mg qd; if on pralsetinib 300 mg qd, decr. to 200 mg qd; if on pralsetinib 200 mg qd, decr. to 100 mg qd: combo may incr. pralsetinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (P-gp-mediated transport inhibited)

• propafenone
Idhifa (enasidenib)

+

propafenone

1 interaction

Avoid/Use Alternative

enasidenib + propafenone

if also combined w/ CYP3A4 inhibitor, avoid use; otherwise, monitor ECG, BP: combo may incr. propafenone levels, risk of QT prolongation, cardiac arrhythmias, hypotension, other adverse effects (hepatic metabolism inhibited)

• relugolix
Idhifa (enasidenib)

+

relugolix

1 interaction

Avoid/Use Alternative

enasidenib + relugolix

PROSTATE CANCER: may hold relugolix if enasidenib tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before enasidenib; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before enasidenib: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited)

• repotrectinib
Idhifa (enasidenib)

+

repotrectinib

1 interaction

Avoid/Use Alternative

enasidenib + repotrectinib

avoid combo: combo may incr. or decr. repotrectinib levels, incr. risk of adverse effects or decr. efficacy (P-gp-mediated transport inhibited, hepatic metabolism induced)

• rivaroxaban
Idhifa (enasidenib)

+

rivaroxaban

1 interaction

Avoid/Use Alternative

enasidenib + rivaroxaban

avoid combo if also combined w/ strong CYP3A4 inhibitor; use alternative if CrCl <80 and combined w/ moderate CYP3A4 inhibitor; otherwise, monitor bleeding s/sx: combo may incr. rivaroxaban levels, risk of bleeding, other adverse effects (BCRP-mediated transport inhibited, P-gp-mediated transport inhibited)

• segesterone (contraceptive)
Idhifa (enasidenib)

+

segesterone (contraceptive)

1 interaction

Avoid/Use Alternative

enasidenib + segesterone (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after enasidenib tx: combo may decr. segesterone levels, contraceptive efficacy (hepatic metabolism induced)

• sirolimus albumin-bound
Idhifa (enasidenib)

+

sirolimus albumin-bound

1 interaction

Avoid/Use Alternative

enasidenib + sirolimus albumin-bound

avoid combo: combo may incr. or decr. sirolimus albumin-bound levels, incr. risk of serious infection, myelosuppression, bleeding (including life-threatening), other adverse effects or decr. efficacy (P-gp-mediated transport inhibited, hepatic metabolism induced)

• tasimelteon
Idhifa (enasidenib)

+

tasimelteon

1 interaction

Avoid/Use Alternative

enasidenib + tasimelteon

avoid combo: combo may incr. or decr. tasimelteon levels, incr. risk of adverse effects or decr. efficacy (hepatic metabolism altered)

• topotecan
Idhifa (enasidenib)

+

topotecan

1 interaction

Avoid/Use Alternative

enasidenib + topotecan

avoid combo w/ oral topotecan: combo may incr. topotecan levels, risk of serious infection, myelosuppression, other adverse effects (gut P-gp-mediated transport inhibited, gut BCRP-mediated transport inhibited)

• tramadol
Idhifa (enasidenib)

+

tramadol

1 interaction

Avoid/Use Alternative

enasidenib + tramadol

use alternative or monitor resp. rate, ECG, withdrawal sx: combo may incr. or decr. tramadol levels, incr. risk of CNS and resp. depression, psychomotor impairment, seizures, serotonin syndrome, QT prolongation, cardiac arrhythmias, other adverse effects or decr. efficacy; may decr. active metabolite levels, efficacy (hepatic metabolism inhibited, decr. conversion to active metabolite; hepatic metabolism induced)

• ulipristal (post-coital contraceptive)
Idhifa (enasidenib)

+

ulipristal (post-coital contraceptive)

1 interaction

Avoid/Use Alternative

enasidenib + ulipristal (post-coital contraceptive)

avoid combo: combo may decr. ulipristal levels, post-coital contraceptive efficacy (hepatic metabolism induced)

• venetoclax
Idhifa (enasidenib)

+

venetoclax

1 interaction

Avoid/Use Alternative

enasidenib + venetoclax

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or venetoclax dose adjustment; AML: consider venetoclax dose adjustment: combo may incr. or decr. venetoclax levels, incr. risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects or decr. efficacy (P-gp-mediated transport inhibited, hepatic metabolism induced)

• vorasidenib
Idhifa (enasidenib)

+

vorasidenib

1 interaction

Avoid/Use Alternative

enasidenib + vorasidenib

use alternative: combo may incr. vorasidenib levels, risk of adverse effects (hepatic metabolism inhibited)

• voxilaprevir
Idhifa (enasidenib)

+

voxilaprevir

1 interaction

Avoid/Use Alternative

enasidenib + voxilaprevir

avoid combo: combo may incr. or decr. voxilaprevir levels, incr. risk of adverse effects or decr. efficacy (hepatic transport inhibited, hepatic metabolism induced)

• zavegepant
Idhifa (enasidenib)

+

zavegepant

1 interaction

Avoid/Use Alternative

enasidenib + zavegepant

avoid combo: combo may incr. zavegepant levels, risk of adverse effects (hepatic transport inhibited)

• zuranolone
Idhifa (enasidenib)

+

zuranolone

1 interaction

Avoid/Use Alternative

enasidenib + zuranolone

avoid combo: combo may decr. zuranolone levels, efficacy (hepatic metabolism induced)

Monitor/Modify Tx

• afatinib
Idhifa (enasidenib)

+

afatinib

1 interaction

Monitor/Modify Tx

enasidenib + afatinib

decr. afatinib dose by 10 mg/day if not tolerated: combo may incr. afatinib levels, risk of adverse effects (P-gp-mediated transport inhibited)

• aficamten
Idhifa (enasidenib)

+

aficamten

1 interaction

Monitor/Modify Tx

enasidenib + aficamten

monitor cardiac fxn, incl. LVEF: combo may decr. aficamten levels, efficacy (hepatic metabolism induced)

• aminophylline
Idhifa (enasidenib)

+

aminophylline

1 interaction

Monitor/Modify Tx

enasidenib + aminophylline

monitor theophylline levels: combo may incr. theophylline levels, risk of cardiac arrhythmias, seizures, other toxicities (hepatic metabolism inhibited; aminophylline converted to theophylline)

• amlodipine
Idhifa (enasidenib)

+

amlodipine

1 interaction

Monitor/Modify Tx

enasidenib + amlodipine

monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metabolism induced)

• anagrelide
Idhifa (enasidenib)

+

anagrelide

1 interaction

Monitor/Modify Tx

enasidenib + anagrelide

monitor ECG: combo may incr. anagrelide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• asenapine
Idhifa (enasidenib)

+

asenapine

1 interaction

Monitor/Modify Tx

enasidenib + asenapine

monitor ECG; consider decr. asenapine dose: combo may incr. asenapine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• atogepant
Idhifa (enasidenib)

+

atogepant

1 interaction

Monitor/Modify Tx

enasidenib + atogepant

consider atogepant dose adjustment: combo may incr. or decr. atogepant levels, incr. risk of adverse effects or decr. efficacy (hepatic transport inhibited, hepatic metabolism induced)

• atorvastatin
Idhifa (enasidenib)

+

atorvastatin

1 interaction

Monitor/Modify Tx

enasidenib + atorvastatin

monitor CK, myopathy sx: combo may incr. or decr. atorvastatin levels, incr. risk of myopathy, rhabdomyolysis, other adverse effects or decr. efficacy (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited, hepatic transport inhibited, hepatic metabolism induced)

• buprenorphine
Idhifa (enasidenib)

+

buprenorphine

1 interaction

Monitor/Modify Tx

enasidenib + buprenorphine

monitor withdrawal sx: combo may decr. buprenorphine levels, efficacy (hepatic metabolism induced)

• caffeine
Idhifa (enasidenib)

+

caffeine

1 interaction

Monitor/Modify Tx

enasidenib + caffeine

consider decr. caffeine intake from all sources: combo may incr. caffeine levels, risk of adverse effects (hepatic metabolism inhibited)

• caffeine citrate
Idhifa (enasidenib)

+

caffeine citrate

1 interaction

Monitor/Modify Tx

enasidenib + caffeine citrate

monitor caffeine levels: combo may incr. caffeine levels, risk of adverse effects (hepatic metabolism inhibited)

• carbamazepine
Idhifa (enasidenib)

+

carbamazepine

1 interaction

Monitor/Modify Tx

enasidenib + carbamazepine

monitor carbamazepine levels: combo may incr. or decr. carbamazepine levels, incr. risk of adverse effects or decr. efficacy (hepatic metabolism altered)

• chlorpromazine
Idhifa (enasidenib)

+

chlorpromazine

1 interaction

Monitor/Modify Tx

enasidenib + chlorpromazine

monitor ECG: combo may incr. chlorpromazine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• citalopram
Idhifa (enasidenib)

+

citalopram

1 interaction

Monitor/Modify Tx

enasidenib + citalopram

adjust max citalopram dose to 20 mg/day: combo may incr. citalopram levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• clobazam
Idhifa (enasidenib)

+

clobazam

1 interaction

Monitor/Modify Tx

enasidenib + clobazam

monitor resp. rate: combo may incr. clobazam and active metabolite levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• clomipramine
Idhifa (enasidenib)

+

clomipramine

1 interaction

Monitor/Modify Tx

enasidenib + clomipramine

monitor ECG: combo may incr. clomipramine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• clozapine
Idhifa (enasidenib)

+

clozapine

1 interaction

Monitor/Modify Tx

enasidenib + clozapine

monitor ECG, BP, HR; decr. clozapine to 1/3 usual dose: combo may incr. clozapine levels, risk of QT prolongation, cardiac arrhythmias, hypotension, bradycardia, other adverse effects (hepatic metabolism inhibited)

• cyclophosphamide
Idhifa (enasidenib)

+

cyclophosphamide

1 interaction

Monitor/Modify Tx

enasidenib + cyclophosphamide

monitor CBC, renal, cardiac fxn: combo may incr. cyclophosphamide active metabolite levels, risk of serious infection, myelosuppression, nephrotoxicity, cardiotoxicity, other adverse effects (hepatic metabolism possibly induced, incr. active metabolite formation)

• cyclosporine
Idhifa (enasidenib)

+

cyclosporine

1 interaction

Monitor/Modify Tx

enasidenib + cyclosporine

monitor cyclosporine levels, renal fxn: combo may incr. or decr. cyclosporine levels, incr. risk of serious infection, nephrotoxicity, other adverse effects or decr. efficacy (P-gp-mediated transport inhibited, hepatic metabolism induced)

• desipramine
Idhifa (enasidenib)

+

desipramine

1 interaction

Monitor/Modify Tx

enasidenib + desipramine

monitor ECG; consider monitoring desipramine levels: combo may incr. desipramine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• diazepam
Idhifa (enasidenib)

+

diazepam

1 interaction

Monitor/Modify Tx

enasidenib + diazepam

monitor resp. rate: combo may incr. diazepam levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• diazoxide
Idhifa (enasidenib)

+

diazoxide

1 interaction

Monitor/Modify Tx

enasidenib + diazoxide

HYPERPHAGIA USE: monitor glucose; see diazoxide choline pkg insert for wt-based dose adjustments; HYPOGLYCEMIA USE: monitor glucose: combo may incr. diazoxide levels, risk of hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• digoxin
Idhifa (enasidenib)

+

digoxin

1 interaction

Monitor/Modify Tx

enasidenib + digoxin

monitor digoxin levels, HR; decr. digoxin frequency or dose by 15-30%: combo may incr. digoxin levels, risk of bradycardia, AV block, other adverse effects (P-gp-mediated transport inhibited)

• diltiazem
Idhifa (enasidenib)

+

diltiazem

1 interaction

Monitor/Modify Tx

enasidenib + diltiazem

monitor BP, HR: combo may decr. diltiazem levels, efficacy (hepatic metabolism induced)

• disopyramide
Idhifa (enasidenib)

+

disopyramide

1 interaction

Monitor/Modify Tx

enasidenib + disopyramide

monitor disopyramide levels: combo may decr. disopyramide levels, efficacy (hepatic metabolism induced)

• edoxaban
Idhifa (enasidenib)

+

edoxaban

1 interaction

Monitor/Modify Tx

enasidenib + edoxaban

monitor bleeding s/sx: combo may incr. edoxaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

• eluxadoline
Idhifa (enasidenib)

+

eluxadoline

1 interaction

Monitor/Modify Tx

enasidenib + eluxadoline

decr. eluxadoline dose to 75 mg bid: combo may incr. eluxadoline levels, risk of adverse effects (hepatic transport inhibited)

• enfortumab vedotin
Idhifa (enasidenib)

+

enfortumab vedotin

1 interaction

Monitor/Modify Tx

enasidenib + enfortumab vedotin

if also combined w/ strong CYP3A4 inhibitor, monitor CBC, glucose: combo may incr. enfortumab vedotin levels, risk of myelosuppression, neuropathy, hyperglycemia, other adverse effects (P-gp-mediated transport inhibited)

• everolimus
Idhifa (enasidenib)

+

everolimus

1 interaction

Monitor/Modify Tx

enasidenib + everolimus

TSC-ASSOC. SEGA, TSC-ASSOC. PARTIAL ONSET SEIZURES, TRANSPLANT: monitor everolimus levels, CBC; BREAST CA, PNET, RENAL CELL CA, RENAL ANGIOMYOLIPOMA W/ TSC: monitor CBC: combo may incr. or decr. everolimus levels, incr. risk of myelosuppression, other adverse effects or decr. efficacy (P-gp-mediated transport inhibited, hepatic metabolism induced)

• fedratinib
Idhifa (enasidenib)

+

fedratinib

1 interaction

Monitor/Modify Tx

enasidenib + fedratinib

if fedratinib also combined w/ moderate or weak CYP3A4 inhibitor, monitor CBC, LFTs; otherwise, caution advised: combo may incr. or decr. fedratinib levels, incr. risk myelosuppression, hepatotoxicity, other adverse effects or decr. efficacy (hepatic metabolism altered)

• fenfluramine
Idhifa (enasidenib)

+

fenfluramine

1 interaction

Monitor/Modify Tx

enasidenib + fenfluramine

if also combined w/ stiripentol, adjust max fenfluramine dose to 17 mg/day; otherwise, adjust max fenfluramine dose to 20 mg/day: combo may incr. fenfluramine levels, risk of adverse effects (hepatic metabolism inhibited)

• flecainide
Idhifa (enasidenib)

+

flecainide

1 interaction

Monitor/Modify Tx

enasidenib + flecainide

monitor flecainide levels, ECG: combo may incr. flecainide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• flibanserin
Idhifa (enasidenib)

+

flibanserin

1 interaction

Monitor/Modify Tx

enasidenib + flibanserin

monitor BP: combo may incr. flibanserin levels, risk of CNS depression, psychomotor impairment, severe hypotension (including syncope), other adverse effects (hepatic metabolism inhibited)

• fluvastatin
Idhifa (enasidenib)

+

fluvastatin

1 interaction

Monitor/Modify Tx

enasidenib + fluvastatin

monitor CK, myopathy sx: combo may incr. fluvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic transport inhibited, BCRP-mediated transport inhibited)

• fosphenytoin
Idhifa (enasidenib)

+

fosphenytoin

1 interaction

Monitor/Modify Tx

enasidenib + fosphenytoin

monitor phenytoin levels: combo may incr. phenytoin levels, risk of toxicity (hepatic metabolism inhibited)

• glyburide
Idhifa (enasidenib)

+

glyburide

1 interaction

Monitor/Modify Tx

enasidenib + glyburide

monitor glucose: combo may incr. glyburide levels, risk of hypoglycemia, other adverse effects (hepatic transport inhibited)

• haloperidol
Idhifa (enasidenib)

+

haloperidol

1 interaction

Monitor/Modify Tx

enasidenib + haloperidol

monitor ECG: combo may incr. or decr. haloperidol levels, incr. risk of QT prolongation, cardiac arrhythmias, other adverse effects or decr. efficacy (hepatic metabolism altered)

• ifosfamide
Idhifa (enasidenib)

+

ifosfamide

1 interaction

Monitor/Modify Tx

enasidenib + ifosfamide

monitor CBC, renal, cardiac fxn; consider ifosfamide dose adjustment: combo may incr. ifosfamide active and toxic metabolite levels, risk of myelosuppression, serious infection, encephalopathy, nephrotoxicity, cardiotoxicity, other adverse effects (hepatic metabolism induced, incr. metabolite formation)

• imipramine
Idhifa (enasidenib)

+

imipramine

1 interaction

Monitor/Modify Tx

enasidenib + imipramine

monitor imipramine levels: combo may incr. imipramine levels, risk of adverse effects (hepatic metabolism inhibited)

• irinotecan
Idhifa (enasidenib)

+

irinotecan

1 interaction

Monitor/Modify Tx

enasidenib + irinotecan

monitor CBC: combo may incr. or decr. irinotecan and active metabolite levels, incr. risk of serious infection, myelosuppression, other toxicities or decr. efficacy (BCRP-mediated transport inhibited, hepatic metabolism induced)

• isradipine
Idhifa (enasidenib)

+

isradipine

1 interaction

Monitor/Modify Tx

enasidenib + isradipine

monitor BP: combo may decr. isradipine levels, efficacy (hepatic metabolism induced)

• ketoconazole
Idhifa (enasidenib)

+

ketoconazole

1 interaction

Monitor/Modify Tx

enasidenib + ketoconazole

monitor for breakthrough fungal infection: combo may decr. ketoconazole levels, efficacy (hepatic metabolism induced)

• lapatinib
Idhifa (enasidenib)

+

lapatinib

1 interaction

Monitor/Modify Tx

enasidenib + lapatinib

monitor ECG: combo may incr. or decr. lapatinib levels, incr. risk of QT prolongation, cardiac arrhythmias, other adverse effects or decr. efficacy (BCRP-mediated transport inhibited, hepatic metabolism induced)

• lidocaine
Idhifa (enasidenib)

+

lidocaine

1 interaction

Monitor/Modify Tx

enasidenib + lidocaine

monitor lidocaine levels if lidocaine antiarrhythmic use; otherwise, monitor BP, HR: combo may incr. lidocaine levels, risk of hypotension, bradycardia, other adverse effects; risk may be higher with continuous infusion or higher doses for local anesthesia (hepatic metabolism inhibited)

• lovastatin
Idhifa (enasidenib)

+

lovastatin

1 interaction

Monitor/Modify Tx

enasidenib + lovastatin

monitor CK, myopathy sx: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic transport inhibited)

• mavorixafor
Idhifa (enasidenib)

+

mavorixafor

1 interaction

Monitor/Modify Tx

enasidenib + mavorixafor

monitor ECG: combo may incr. mavorixafor levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (P-gp-mediated transport inhibited)

• methotrexate
Idhifa (enasidenib)

+

methotrexate

1 interaction

Monitor/Modify Tx

enasidenib + methotrexate

monitor CBC, renal fxn: combo may incr. methotrexate levels, risk of serious infection, myelosuppression, nephrotoxicity, other adverse effects (BCRP-mediated transport inhibited)

• metoprolol
Idhifa (enasidenib)

+

metoprolol

1 interaction

Monitor/Modify Tx

enasidenib + metoprolol

monitor BP, HR; consider lower metoprolol dose: combo may incr. metoprolol levels, risk of hypotension, bradycardia, AV block, other adverse effects (hepatic metabolism inhibited)

• mexiletine
Idhifa (enasidenib)

+

mexiletine

1 interaction

Monitor/Modify Tx

enasidenib + mexiletine

titrate slowly; consider monitoring mexiletine levels: combo may incr. mexiletine levels, risk of adverse effects (hepatic metabolism inhibited)

• mirtazapine
Idhifa (enasidenib)

+

mirtazapine

1 interaction

Monitor/Modify Tx

enasidenib + mirtazapine

monitor ECG: combo may incr. mirtazapine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• mitapivat
Idhifa (enasidenib)

+

mitapivat

1 interaction

Monitor/Modify Tx

enasidenib + mitapivat

monitor Hgb: combo may decr. mitapivat levels, efficacy (hepatic metabolism induced)

• mitoxantrone
Idhifa (enasidenib)

+

mitoxantrone

1 interaction

Monitor/Modify Tx

enasidenib + mitoxantrone

monitor CBC, cardiac fxn, incl. LVEF: combo may incr. mitoxantrone levels, risk of serious infection, myelosuppression, cardiotoxicity, other adverse effects (BCRP-mediated transport inhibited)

• momelotinib
Idhifa (enasidenib)

+

momelotinib

1 interaction

Monitor/Modify Tx

enasidenib + momelotinib

monitor CBC, bleeding s/sx: combo may incr. momelotinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic transport inhibited)

• morphine
Idhifa (enasidenib)

+

morphine

1 interaction

Monitor/Modify Tx

enasidenib + morphine

monitor resp. rate, consider decr. dose of one or both drugs: combo may incr. morphine levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (P-gp-mediated transport inhibited)

• nateglinide
Idhifa (enasidenib)

+

nateglinide

1 interaction

Monitor/Modify Tx

enasidenib + nateglinide

monitor glucose: combo may incr. nateglinide levels, risk of hypoglycemia, other adverse effects (hepatic transport inhibited)

• nicardipine
Idhifa (enasidenib)

+

nicardipine

1 interaction

Monitor/Modify Tx

enasidenib + nicardipine

monitor BP: combo may decr. nicardipine levels, efficacy (hepatic metabolism induced)

• nimodipine
Idhifa (enasidenib)

+

nimodipine

1 interaction

Monitor/Modify Tx

enasidenib + nimodipine

monitor BP: combo may decr. nimodipine levels, efficacy (hepatic metabolism induced)

• nisoldipine
Idhifa (enasidenib)

+

nisoldipine

1 interaction

Monitor/Modify Tx

enasidenib + nisoldipine

monitor BP: combo may decr. nisoldipine levels, efficacy (hepatic metabolism induced)

• nortriptyline
Idhifa (enasidenib)

+

nortriptyline

1 interaction

Monitor/Modify Tx

enasidenib + nortriptyline

monitor nortriptyline levels: combo may incr. nortriptyline levels, risk of adverse effects (hepatic metabolism inhibited)

• olanzapine
Idhifa (enasidenib)

+

olanzapine

1 interaction

Monitor/Modify Tx

enasidenib + olanzapine

consider decr. olanzapine dose: combo may incr. olanzapine levels, risk of adverse effects (hepatic metabolism inhibited)

• phenytoin
Idhifa (enasidenib)

+

phenytoin

1 interaction

Monitor/Modify Tx

enasidenib + phenytoin

monitor phenytoin levels: combo may incr. phenytoin levels, risk of toxicity (hepatic metabolism inhibited)

• pitavastatin
Idhifa (enasidenib)

+

pitavastatin

1 interaction

Monitor/Modify Tx

enasidenib + pitavastatin

monitor CK, myopathy sx: combo may incr. pitavastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic transport inhibited, BCRP-mediated transport inhibited)

• pravastatin
Idhifa (enasidenib)

+

pravastatin

1 interaction

Monitor/Modify Tx

enasidenib + pravastatin

monitor CK, myopathy sx: combo may incr. pravastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic transport inhibited, BCRP-mediated transport inhibited)

• propranolol
Idhifa (enasidenib)

+

propranolol

1 interaction

Monitor/Modify Tx

enasidenib + propranolol

monitor BP, HR: combo may incr. propranolol levels, risk of hypotension, bradycardia, AV block, other adverse effects (hepatic metabolism inhibited)

• quinidine (antiarrhythmic)
Idhifa (enasidenib)

+

quinidine (antiarrhythmic)

1 interaction

Monitor/Modify Tx

enasidenib + quinidine (antiarrhythmic)

monitor quinidine levels, ECG: combo may incr. or decr. quinidine levels, incr. risk of QT prolongation, cardiac arrhythmias, other adverse effects or decr. efficacy (P-gp-mediated transport inhibited, hepatic metabolism induced)

• rasagiline
Idhifa (enasidenib)

+

rasagiline

1 interaction

Monitor/Modify Tx

enasidenib + rasagiline

adjust max rasagiline dose to 0.5 mg/day: combo may incr. rasagiline levels, risk of adverse effects (hepatic metabolism inhibited)

• red yeast rice
Idhifa (enasidenib)

+

red yeast rice

1 interaction

Monitor/Modify Tx

enasidenib + red yeast rice

monitor CK, myopathy sx w/ large amounts of red yeast rice: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic transport inhibited, red yeast rice contains varying amounts of lovastatin)

• repaglinide
Idhifa (enasidenib)

+

repaglinide

1 interaction

Monitor/Modify Tx

enasidenib + repaglinide

monitor glucose: combo may incr. repaglinide levels, risk of hypoglycemia, other adverse effects (hepatic transport inhibited)

• riociguat
Idhifa (enasidenib)

+

riociguat

1 interaction

Monitor/Modify Tx

enasidenib + riociguat

consider decr. riociguat start dose to 0.5 mg PO tid; monitor BP: combo may incr. riociguat levels, risk of severe hypotension, other adverse effects (BCRP-mediated transport inhibited)

• ropinirole
Idhifa (enasidenib)

+

ropinirole

1 interaction

Monitor/Modify Tx

enasidenib + ropinirole

consider decr. ropinirole dose: combo may incr. ropinirole levels, risk of adverse effects (hepatic metabolism inhibited)

• rosuvastatin
Idhifa (enasidenib)

+

rosuvastatin

1 interaction

Monitor/Modify Tx

enasidenib + rosuvastatin

monitor CK, myopathy sx; adjust max rosuvastatin dose to 10 mg qd: combo may incr. rosuvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic transport inhibited, BCRP-mediated transport inhibited)

• simvastatin
Idhifa (enasidenib)

+

simvastatin

1 interaction

Monitor/Modify Tx

enasidenib + simvastatin

monitor CK, myopathy sx: combo may incr. or decr. simvastatin levels, incr. risk of myopathy, rhabdomyolysis, other adverse effects or decr. efficacy (hepatic transport inhibited, BCRP-mediated transport inhibited, hepatic metabolism induced)

• sirolimus
Idhifa (enasidenib)

+

sirolimus

1 interaction

Monitor/Modify Tx

enasidenib + sirolimus

monitor sirolimus levels: combo may incr. or decr. sirolimus levels, incr. risk of serious infection, other adverse effects or decr. efficacy (P-gp-mediated transport inhibited, hepatic metabolism induced)

• tacrolimus
Idhifa (enasidenib)

+

tacrolimus

1 interaction

Monitor/Modify Tx

enasidenib + tacrolimus

monitor tacrolimus levels, ECG, renal fxn: combo may incr. or decr. tacrolimus levels, incr. risk of QT prolongation, cardiac arrhythmias, nephrotoxicity, other adverse effects or decr. efficacy (P-gp-mediated transport inhibited, hepatic metabolism induced)

• talazoparib
Idhifa (enasidenib)

+

talazoparib

1 interaction

Monitor/Modify Tx

enasidenib + talazoparib

monitor CBC: combo may incr. talazoparib levels, risk of myelosuppression, other adverse effects (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited)

• tenofovir alafenamide
Idhifa (enasidenib)

+

tenofovir alafenamide

1 interaction

Monitor/Modify Tx

enasidenib + tenofovir alafenamide

if tenofovir alafenamide not admin. w/ cobicistat, monitor renal fxn: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (gut P-gp-mediated transport inhibited, gut BCRP-mediated transport inhibited)

• tenofovir disoproxil
Idhifa (enasidenib)

+

tenofovir disoproxil

1 interaction

Monitor/Modify Tx

enasidenib + tenofovir disoproxil

monitor renal fxn: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (gut P-gp-mediated transport inhibited, gut BCRP-mediated transport inhibited)

• theophylline
Idhifa (enasidenib)

+

theophylline

1 interaction

Monitor/Modify Tx

enasidenib + theophylline

monitor theophylline levels: combo may incr. theophylline levels, risk of cardiac arrhythmias, seizures, other toxicities (hepatic metabolism inhibited)

• tiagabine
Idhifa (enasidenib)

+

tiagabine

1 interaction

Monitor/Modify Tx

enasidenib + tiagabine

consider tiagabine dose adjustment if not on concurrent enzyme-inducing AEDs; titrate tiagabine dose to effect if already on enzyme-inducing AEDs: combo may decr. tiagabine levels, efficacy (hepatic metabolism induced; further induction possible if on concurrent enzyme-inducing AEDs)

• triclabendazole
Idhifa (enasidenib)

+

triclabendazole

1 interaction

Monitor/Modify Tx

enasidenib + triclabendazole

monitor ECG: combo may incr. triclabendazole levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• ubrogepant
Idhifa (enasidenib)

+

ubrogepant

1 interaction

Monitor/Modify Tx

enasidenib + ubrogepant

consider ubrogepant dose adjustment: combo may incr. or decr. ubrogepant levels, incr. risk of adverse effects or decr. efficacy (BCRP-mediated transport inhibited, P-gp-mediated transport inhibited, hepatic metabolism induced)

• voriconazole
Idhifa (enasidenib)

+

voriconazole

1 interaction

Monitor/Modify Tx

enasidenib + voriconazole

monitor for breakthrough fungal infection: combo may decr. voriconazole levels, efficacy (hepatic metabolism induced)

• warfarin
Idhifa (enasidenib)

+

warfarin

1 interaction

Monitor/Modify Tx

enasidenib + warfarin

monitor INR, bleeding s/sx, especially during initiation/titration: combo may incr. or decr. warfarin levels, incr. risk of bleeding (including life-threatening), other adverse effects or decr. efficacy (hepatic metabolism altered)

Caution Advised

• abemaciclib
Idhifa (enasidenib)

+

abemaciclib

1 interaction

Caution Advised

enasidenib + abemaciclib

caution advised: combo may decr. abemaciclib levels, efficacy (hepatic metabolism induced)

• abrocitinib
Idhifa (enasidenib)

+

abrocitinib

1 interaction

Caution Advised

enasidenib + abrocitinib

caution advised: combo may incr. abrocitinib and active metabolite levels, risk of serious infection, other adverse effects (hepatic metabolism inhibited)

• acalabrutinib
Idhifa (enasidenib)

+

acalabrutinib

1 interaction

Caution Advised

enasidenib + acalabrutinib

caution advised: combo may decr. acalabrutinib levels, efficacy (hepatic metabolism induced)

• alfentanil
Idhifa (enasidenib)

+

alfentanil

1 interaction

Caution Advised

enasidenib + alfentanil

caution advised: combo may decr. alfentanil levels, efficacy (hepatic metabolism induced)

• alprazolam
Idhifa (enasidenib)

+

alprazolam

1 interaction

Caution Advised

enasidenib + alprazolam

caution advised: combo may decr. alprazolam levels, efficacy (hepatic metabolism induced)

• amiodarone
Idhifa (enasidenib)

+

amiodarone

1 interaction

Caution Advised

enasidenib + amiodarone

caution advised: combo may decr. amiodarone levels, efficacy (hepatic metabolism induced)

• aprepitant
Idhifa (enasidenib)

+

aprepitant

1 interaction

Caution Advised

enasidenib + aprepitant

caution advised: combo may decr. aprepitant levels, efficacy (hepatic metabolism induced)

• artemether/lumefantrine
Idhifa (enasidenib)

+

artemether/ lumefantrine

1 interaction

Caution Advised

enasidenib + artemether/ lumefantrine

caution advised: combo may decr. artemether/lumefantrine levels, efficacy (hepatic metabolism induced)

• avacopan
Idhifa (enasidenib)

+

avacopan

1 interaction

Caution Advised

enasidenib + avacopan

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• avapritinib
Idhifa (enasidenib)

+

avapritinib

1 interaction

Caution Advised

enasidenib + avapritinib

caution advised: combo may decr. avapritinib levels, efficacy (hepatic metabolism induced)

• axitinib
Idhifa (enasidenib)

+

axitinib

1 interaction

Caution Advised

enasidenib + axitinib

caution advised: combo may decr. axitinib levels, efficacy (hepatic metabolism induced)

• bictegravir
Idhifa (enasidenib)

+

bictegravir

1 interaction

Caution Advised

enasidenib + bictegravir

caution advised if also combined w/ UGT1A1 inducer: combo may decr. bictegravir levels, efficacy (hepatic metabolism induced)

• bosentan
Idhifa (enasidenib)

+

bosentan

1 interaction

Caution Advised

enasidenib + bosentan

caution advised: combo may incr. bosentan levels, risk of adverse effects (hepatic transport inhibited)

• bosutinib
Idhifa (enasidenib)

+

bosutinib

1 interaction

Caution Advised

enasidenib + bosutinib

caution advised: combo may decr. bosutinib levels, efficacy (hepatic metabolism induced)

• brigatinib
Idhifa (enasidenib)

+

brigatinib

1 interaction

Caution Advised

enasidenib + brigatinib

caution advised: combo may decr. brigatinib levels, efficacy (hepatic metabolism induced)

• budesonide
Idhifa (enasidenib)

+

budesonide

1 interaction

Caution Advised

enasidenib + budesonide

caution advised: combo may decr. budesonide levels, efficacy (hepatic metabolism induced)

• buspirone
Idhifa (enasidenib)

+

buspirone

1 interaction

Caution Advised

enasidenib + buspirone

caution advised: combo may decr. buspirone levels, efficacy (hepatic metabolism induced)

• cabozantinib
Idhifa (enasidenib)

+

cabozantinib

1 interaction

Caution Advised

enasidenib + cabozantinib

caution advised: combo may decr. cabozantinib levels, efficacy (hepatic metabolism induced)

• capivasertib
Idhifa (enasidenib)

+

capivasertib

1 interaction

Caution Advised

enasidenib + capivasertib

caution advised: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• capmatinib
Idhifa (enasidenib)

+

capmatinib

1 interaction

Caution Advised

enasidenib + capmatinib

caution advised: combo may decr. capmatinib levels, efficacy (hepatic metabolism induced)

• carisoprodol
Idhifa (enasidenib)

+

carisoprodol

1 interaction

Caution Advised

enasidenib + carisoprodol

caution advised: combo may incr. carisoprodol levels, decr. active metabolite meprobamate levels, alter risk of adverse effects and efficacy (hepatic metabolism inhibited, decr. conversion to active metabolite)

• clarithromycin
Idhifa (enasidenib)

+

clarithromycin

1 interaction

Caution Advised

enasidenib + clarithromycin

caution advised: combo may decr. clarithromycin levels, efficacy (hepatic metabolism induced)

• clopidogrel
Idhifa (enasidenib)

+

clopidogrel

1 interaction

Caution Advised

enasidenib + clopidogrel

caution advised: combo may decr. clopidogrel active metabolite levels, efficacy (hepatic metabolism inhibited, decr. conversion of clopidogrel to active metabolite)

• cobicistat
Idhifa (enasidenib)

+

cobicistat

1 interaction

Caution Advised

enasidenib + cobicistat

caution advised: combo may decr. cobicistat levels, efficacy (hepatic metabolism induced)

• cobimetinib
Idhifa (enasidenib)

+

cobimetinib

1 interaction

Caution Advised

enasidenib + cobimetinib

caution advised: combo may decr. cobimetinib levels, efficacy (hepatic metabolism induced)

• crizotinib
Idhifa (enasidenib)

+

crizotinib

1 interaction

Caution Advised

enasidenib + crizotinib

caution advised: combo may decr. crizotinib levels, efficacy (hepatic metabolism induced)

• daridorexant
Idhifa (enasidenib)

+

daridorexant

1 interaction

Caution Advised

enasidenib + daridorexant

caution advised: combo may decr. daridorexant levels, efficacy (hepatic metabolism induced)

• darolutamide
Idhifa (enasidenib)

+

darolutamide

1 interaction

Caution Advised

enasidenib + darolutamide

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport inhibited)

• darunavir
Idhifa (enasidenib)

+

darunavir

1 interaction

Caution Advised

enasidenib + darunavir

caution advised: combo may decr. darunavir levels, efficacy (hepatic metabolism induced)

• dasatinib
Idhifa (enasidenib)

+

dasatinib

1 interaction

Caution Advised

enasidenib + dasatinib

caution advised: combo may decr. dasatinib levels, efficacy (hepatic metabolism induced)

• defactinib
Idhifa (enasidenib)

+

defactinib

1 interaction

Caution Advised

enasidenib + defactinib

caution advised: combo may decr. defactinib levels, efficacy (hepatic metabolism induced)

• deflazacort
Idhifa (enasidenib)

+

deflazacort

1 interaction

Caution Advised

enasidenib + deflazacort

caution advised: combo may decr. deflazacort active metabolite levels, efficacy (hepatic metabolism induced)

• doravirine
Idhifa (enasidenib)

+

doravirine

1 interaction

Caution Advised

enasidenib + doravirine

caution advised: combo may decr. doravirine levels, efficacy (hepatic metabolism induced)

• dordaviprone
Idhifa (enasidenib)

+

dordaviprone

1 interaction

Caution Advised

enasidenib + dordaviprone

caution advised: combo may decr. dordaviprone levels, efficacy (hepatic metabolism induced)

• dronedarone
Idhifa (enasidenib)

+

dronedarone

1 interaction

Caution Advised

enasidenib + dronedarone

caution advised: combo may decr. dronedarone levels, efficacy (hepatic metabolism induced)

• drospirenone (hormone replacement)
Idhifa (enasidenib)

+

drospirenone (hormone replacement)

1 interaction

Caution Advised

enasidenib + drospirenone (hormone replacement)

caution advised: combo may decr. drospirenone levels, efficacy (hepatic metabolism induced)

• elacestrant
Idhifa (enasidenib)

+

elacestrant

1 interaction

Caution Advised

enasidenib + elacestrant

caution advised: combo may decr. elacestrant levels, efficacy (hepatic metabolism induced)

• elbasvir
Idhifa (enasidenib)

+

elbasvir

1 interaction

Caution Advised

enasidenib + elbasvir

caution advised: combo may decr. elbasvir levels, efficacy (hepatic metabolism induced)

• elexacaftor/tezacaftor/ivacaftor
Idhifa (enasidenib)

+

elexacaftor/ tezacaftor/ ivacaftor

1 interaction

Caution Advised

enasidenib + elexacaftor/ tezacaftor/ ivacaftor

caution advised: combo may decr. elexacaftor/tezacaftor/ivacaftor levels, efficacy (hepatic metabolism induced)

• elvitegravir
Idhifa (enasidenib)

+

elvitegravir

1 interaction

Caution Advised

enasidenib + elvitegravir

caution advised: combo may decr. elvitegravir levels, efficacy (hepatic metabolism induced)

• entrectinib
Idhifa (enasidenib)

+

entrectinib

1 interaction

Caution Advised

enasidenib + entrectinib

caution advised: combo may decr. entrectinib levels, efficacy (hepatic metabolism induced)

• erdafitinib
Idhifa (enasidenib)

+

erdafitinib

1 interaction

Caution Advised

enasidenib + erdafitinib

caution advised: combo may decr. erdafitinib levels, efficacy (hepatic metabolism induced)

• felodipine
Idhifa (enasidenib)

+

felodipine

1 interaction

Caution Advised

enasidenib + felodipine

caution advised: combo may decr. felodipine levels, efficacy (hepatic metabolism induced)

• finerenone
Idhifa (enasidenib)

+

finerenone

1 interaction

Caution Advised

enasidenib + finerenone

caution advised: combo may decr. finerenone levels, efficacy (hepatic metabolism induced)

• fosaprepitant
Idhifa (enasidenib)

+

fosaprepitant

1 interaction

Caution Advised

enasidenib + fosaprepitant

caution advised: combo may decr. aprepitant levels, efficacy (hepatic metabolism induced)

• fostamatinib
Idhifa (enasidenib)

+

fostamatinib

1 interaction

Caution Advised

enasidenib + fostamatinib

caution advised: combo may decr. fostamatinib active metabolite levels, efficacy (hepatic metabolism induced)

• fruquintinib
Idhifa (enasidenib)

+

fruquintinib

1 interaction

Caution Advised

enasidenib + fruquintinib

caution advised: combo may decr. fruquintinib levels, efficacy (hepatic metabolism induced)

• gepirone
Idhifa (enasidenib)

+

gepirone

1 interaction

Caution Advised

enasidenib + gepirone

caution advised: combo may decr. gepirone levels, efficacy (hepatic metabolism induced)

• gilteritinib
Idhifa (enasidenib)

+

gilteritinib

1 interaction

Caution Advised

enasidenib + gilteritinib

caution advised: combo may decr. gilteritinib levels, efficacy (hepatic metabolism induced)

• glasdegib
Idhifa (enasidenib)

+

glasdegib

1 interaction

Caution Advised

enasidenib + glasdegib

caution advised: combo may decr. glasdegib levels, efficacy (hepatic metabolism induced)

• glecaprevir
Idhifa (enasidenib)

+

glecaprevir

1 interaction

Caution Advised

enasidenib + glecaprevir

caution advised: combo may incr. or decr. glecaprevir levels, incr. risk of adverse effects or decr. efficacy (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited, hepatic transport inhibited, hepatic metabolism induced)

• guanfacine
Idhifa (enasidenib)

+

guanfacine

1 interaction

Caution Advised

enasidenib + guanfacine

caution advised: combo may decr. guanfacine levels, efficacy (hepatic metabolism induced)

• hydrocortisone
Idhifa (enasidenib)

+

hydrocortisone

1 interaction

Caution Advised

enasidenib + hydrocortisone

caution advised: combo may decr. hydrocortisone levels, efficacy (hepatic metabolism induced)

• ibrutinib
Idhifa (enasidenib)

+

ibrutinib

1 interaction

Caution Advised

enasidenib + ibrutinib

caution advised: combo may decr. ibrutinib levels, efficacy (hepatic metabolism induced)

• isavuconazonium
Idhifa (enasidenib)

+

isavuconazonium

1 interaction

Caution Advised

enasidenib + isavuconazonium

caution advised: combo may decr. isavuconazole levels, efficacy (hepatic metabolism induced)

• istradefylline
Idhifa (enasidenib)

+

istradefylline

1 interaction

Caution Advised

enasidenib + istradefylline

caution advised: combo may decr. istradefylline levels, efficacy (hepatic metabolism induced)

• itraconazole
Idhifa (enasidenib)

+

itraconazole

1 interaction

Caution Advised

enasidenib + itraconazole

caution advised: combo may decr. itraconazole levels, efficacy (hepatic metabolism induced)

• ivacaftor
Idhifa (enasidenib)

+

ivacaftor

1 interaction

Caution Advised

enasidenib + ivacaftor

caution advised: combo may decr. ivacaftor levels, efficacy (hepatic metabolism induced)

• larotrectinib
Idhifa (enasidenib)

+

larotrectinib

1 interaction

Caution Advised

enasidenib + larotrectinib

caution advised: combo may decr. larotrectinib levels, efficacy (hepatic metabolism induced)

• lazertinib
Idhifa (enasidenib)

+

lazertinib

1 interaction

Caution Advised

enasidenib + lazertinib

caution advised: combo may decr. lazertinib levels, efficacy (hepatic metabolism induced)

• lefamulin
Idhifa (enasidenib)

+

lefamulin

1 interaction

Caution Advised

enasidenib + lefamulin

caution advised w/ oral lefamulin: combo may decr. lefamulin levels, efficacy (hepatic metabolism induced)

• lenacapavir
Idhifa (enasidenib)

+

lenacapavir

1 interaction

Caution Advised

enasidenib + lenacapavir

caution advised: combo may decr. lenacapavir levels, efficacy (hepatic metabolism induced)

• leniolisib
Idhifa (enasidenib)

+

leniolisib

1 interaction

Caution Advised

enasidenib + leniolisib

caution advised: combo may decr. leniolisib levels, efficacy (hepatic metabolism induced)

• letermovir
Idhifa (enasidenib)

+

letermovir

1 interaction

Caution Advised

enasidenib + letermovir

caution advised: combo may decr. letermovir levels, efficacy (hepatic metabolism induced)

• levoketoconazole
Idhifa (enasidenib)

+

levoketoconazole

1 interaction

Caution Advised

enasidenib + levoketoconazole

caution advised: combo may decr. levoketoconazole levels, efficacy (hepatic metabolism induced)

• levonorgestrel intrauterine device (contraceptive)
Idhifa (enasidenib)

+

levonorgestrel intrauterine device (contraceptive)

1 interaction

Caution Advised

enasidenib + levonorgestrel intrauterine device (contraceptive)

caution advised: combo may decr. levonorgestrel levels, contraceptive efficacy (hepatic metabolism possibly induced)

• lonafarnib
Idhifa (enasidenib)

+

lonafarnib

1 interaction

Caution Advised

enasidenib + lonafarnib

caution advised: combo may decr. lonafarnib levels, efficacy (hepatic metabolism induced)

• lorlatinib
Idhifa (enasidenib)

+

lorlatinib

1 interaction

Caution Advised

enasidenib + lorlatinib

caution advised: combo may decr. lorlatinib levels, efficacy (hepatic metabolism induced)

• lurasidone
Idhifa (enasidenib)

+

lurasidone

1 interaction

Caution Advised

enasidenib + lurasidone

caution advised: combo may decr. lurasidone levels, efficacy (hepatic metabolism induced)

• macitentan
Idhifa (enasidenib)

+

macitentan

1 interaction

Caution Advised

enasidenib + macitentan

caution advised: combo may decr. macitentan levels, efficacy (hepatic metabolism induced)

• maraviroc
Idhifa (enasidenib)

+

maraviroc

1 interaction

Caution Advised

enasidenib + maraviroc

caution advised: combo may decr. maraviroc levels, efficacy (hepatic metabolism induced)

• melatonin
Idhifa (enasidenib)

+

melatonin

1 interaction

Caution Advised

enasidenib + melatonin

caution advised: combo may incr. melatonin levels, risk of adverse effects (hepatic metabolism inhibited)

• midazolam
Idhifa (enasidenib)

+

midazolam

1 interaction

Caution Advised

enasidenib + midazolam

caution advised w/ oral midazolam; other midazolam routes OK: combo may decr. midazolam levels, efficacy (hepatic metabolism induced)

• midostaurin
Idhifa (enasidenib)

+

midostaurin

1 interaction

Caution Advised

enasidenib + midostaurin

caution advised: combo may decr. midostaurin levels, efficacy (hepatic metabolism induced)

• mobocertinib
Idhifa (enasidenib)

+

mobocertinib

1 interaction

Caution Advised

enasidenib + mobocertinib

caution advised: combo may decr. mobocertinib levels, efficacy (hepatic metabolism induced)

• naldemedine
Idhifa (enasidenib)

+

naldemedine

1 interaction

Caution Advised

enasidenib + naldemedine

caution advised: combo may incr. or decr. naldemedine levels, incr. risk of adverse effects or decr. efficacy (P-gp-mediated transport inhibited, hepatic metabolism induced)

• naloxegol
Idhifa (enasidenib)

+

naloxegol

1 interaction

Caution Advised

enasidenib + naloxegol

caution advised: combo may decr. naloxegol levels, efficacy (hepatic metabolism induced)

• nefazodone
Idhifa (enasidenib)

+

nefazodone

1 interaction

Caution Advised

enasidenib + nefazodone

caution advised: combo may decr. nefazodone levels, efficacy (hepatic metabolism induced)

• nelfinavir
Idhifa (enasidenib)

+

nelfinavir

1 interaction

Caution Advised

enasidenib + nelfinavir

caution advised: combo may decr. nelfinavir levels, efficacy (hepatic metabolism induced)

• netupitant
Idhifa (enasidenib)

+

netupitant

1 interaction

Caution Advised

enasidenib + netupitant

caution advised: combo may decr. netupitant levels, efficacy (hepatic metabolism induced)

• nevirapine
Idhifa (enasidenib)

+

nevirapine

1 interaction

Caution Advised

enasidenib + nevirapine

caution advised: combo may decr. nevirapine levels, efficacy (hepatic metabolism induced)

• nifedipine
Idhifa (enasidenib)

+

nifedipine

1 interaction

Caution Advised

enasidenib + nifedipine

caution advised: combo may decr. nifedipine levels, efficacy (hepatic metabolism induced)

• nilotinib
Idhifa (enasidenib)

+

nilotinib

1 interaction

Caution Advised

enasidenib + nilotinib

caution advised: combo may decr. nilotinib levels, efficacy (hepatic metabolism induced)

• nirmatrelvir
Idhifa (enasidenib)

+

nirmatrelvir

1 interaction

Caution Advised

enasidenib + nirmatrelvir

caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

• nirogacestat
Idhifa (enasidenib)

+

nirogacestat

1 interaction

Caution Advised

enasidenib + nirogacestat

caution advised: combo may decr. nirogacestat levels, efficacy (hepatic metabolism induced)

• olaparib
Idhifa (enasidenib)

+

olaparib

1 interaction

Caution Advised

enasidenib + olaparib

caution advised: combo may decr. olaparib levels, efficacy (hepatic metabolism induced)

• olutasidenib
Idhifa (enasidenib)

+

olutasidenib

1 interaction

Caution Advised

enasidenib + olutasidenib

caution advised: combo may decr. olutasidenib levels, efficacy (hepatic metabolism induced)

• palbociclib
Idhifa (enasidenib)

+

palbociclib

1 interaction

Caution Advised

enasidenib + palbociclib

caution advised: combo may decr. palbociclib levels, efficacy (hepatic metabolism induced)

• pemigatinib
Idhifa (enasidenib)

+

pemigatinib

1 interaction

Caution Advised

enasidenib + pemigatinib

caution advised: combo may decr. pemigatinib levels, efficacy (hepatic metabolism induced)

• pentoxifylline
Idhifa (enasidenib)

+

pentoxifylline

1 interaction

Caution Advised

enasidenib + pentoxifylline

caution advised: combo may incr. pentoxifylline levels, risk of adverse effects (hepatic metabolism inhibited)

• perampanel
Idhifa (enasidenib)

+

perampanel

1 interaction

Caution Advised

enasidenib + perampanel

caution advised: combo may decr. perampanel levels, efficacy (hepatic metabolism induced)

• perphenazine
Idhifa (enasidenib)

+

perphenazine

1 interaction

Caution Advised

enasidenib + perphenazine

caution advised: combo may incr. perphenazine levels, risk of adverse effects (hepatic metabolism inhibited)

• pibrentasvir
Idhifa (enasidenib)

+

pibrentasvir

1 interaction

Caution Advised

enasidenib + pibrentasvir

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited, BCRP-mediated transport inhibited)

• pimavanserin
Idhifa (enasidenib)

+

pimavanserin

1 interaction

Caution Advised

enasidenib + pimavanserin

caution advised: combo may decr. pimavanserin levels, efficacy (hepatic metabolism induced)

• pirtobrutinib
Idhifa (enasidenib)

+

pirtobrutinib

1 interaction

Caution Advised

enasidenib + pirtobrutinib

caution advised: combo may decr. pirtobrutinib levels, efficacy (hepatic metabolism induced)

• ponatinib
Idhifa (enasidenib)

+

ponatinib

1 interaction

Caution Advised

enasidenib + ponatinib

caution advised: combo may decr. ponatinib levels, efficacy (hepatic metabolism induced)

• praziquantel
Idhifa (enasidenib)

+

praziquantel

1 interaction

Caution Advised

enasidenib + praziquantel

caution advised: combo may decr. praziquantel levels, efficacy (hepatic metabolism induced)

• pretomanid
Idhifa (enasidenib)

+

pretomanid

1 interaction

Caution Advised

enasidenib + pretomanid

caution advised: combo may decr. pretomanid levels, efficacy (hepatic metabolism induced)

• proguanil
Idhifa (enasidenib)

+

proguanil

1 interaction

Caution Advised

enasidenib + proguanil

caution advised: combo may incr. proguanil levels, risk of adverse effects; may decr. proguanil active metabolite levels, efficacy (hepatic metabolism inhibited, decr. conversion to active metabolite)

• quetiapine
Idhifa (enasidenib)

+

quetiapine

1 interaction

Caution Advised

enasidenib + quetiapine

caution advised: combo may decr. quetiapine levels, efficacy (hepatic metabolism induced)

• quinine
Idhifa (enasidenib)

+

quinine

1 interaction

Caution Advised

enasidenib + quinine

caution advised: combo may decr. quinine levels, efficacy (hepatic metabolism induced)

• quizartinib
Idhifa (enasidenib)

+

quizartinib

1 interaction

Caution Advised

enasidenib + quizartinib

caution advised: combo may decr. quizartinib levels, efficacy (hepatic metabolism induced)

• ramelteon
Idhifa (enasidenib)

+

ramelteon

1 interaction

Caution Advised

enasidenib + ramelteon

caution advised: combo may incr. ramelteon levels, risk of adverse effects (hepatic metabolism inhibited)

• ribociclib
Idhifa (enasidenib)

+

ribociclib

1 interaction

Caution Advised

enasidenib + ribociclib

caution advised: combo may decr. ribociclib levels, efficacy (hepatic metabolism induced)

• rifampin
Idhifa (enasidenib)

+

rifampin

1 interaction

Caution Advised

enasidenib + rifampin

caution advised: combo may incr. rifampin levels, risk of adverse effects (hepatic transport inhibited)

• rilpivirine
Idhifa (enasidenib)

+

rilpivirine

1 interaction

Caution Advised

enasidenib + rilpivirine

caution advised: combo may decr. rilpivirine levels, efficacy (hepatic metabolism induced)

• riluzole
Idhifa (enasidenib)

+

riluzole

1 interaction

Caution Advised

enasidenib + riluzole

caution advised: combo may incr. riluzole levels, risk of adverse effects (hepatic metabolism inhibited)

• ripretinib
Idhifa (enasidenib)

+

ripretinib

1 interaction

Caution Advised

enasidenib + ripretinib

caution advised: combo may decr. ripretinib and active metabolite levels, efficacy (hepatic metabolism induced)

• ritonavir
Idhifa (enasidenib)

+

ritonavir

1 interaction

Caution Advised

enasidenib + ritonavir

caution advised: combo may decr. ritonavir levels, efficacy (hepatic metabolism induced)

• roflumilast
Idhifa (enasidenib)

+

roflumilast

1 interaction

Caution Advised

enasidenib + roflumilast

caution advised: combo may incr. or decr. roflumilast levels, incr. risk of adverse effects or decr. efficacy (hepatic metabolism altered)

• roflumilast topical
Idhifa (enasidenib)

+

roflumilast topical

1 interaction

Caution Advised

enasidenib + roflumilast topical

if also combined w/ CYP3A4 inhibitor, caution advised: combo may incr. roflumilast levels, risk of adverse effects (hepatic metabolism inhibited)

• rolapitant
Idhifa (enasidenib)

+

rolapitant

1 interaction

Caution Advised

enasidenib + rolapitant

caution advised: combo may decr. rolapitant levels, efficacy (hepatic metabolism induced)

• ropivacaine
Idhifa (enasidenib)

+

ropivacaine

1 interaction

Caution Advised

enasidenib + ropivacaine

caution advised: combo may incr. ropivacaine levels, risk of adverse effects (hepatic metabolism inhibited)

• samidorphan
Idhifa (enasidenib)

+

samidorphan

1 interaction

Caution Advised

enasidenib + samidorphan

caution advised: combo may decr. samidorphan levels, efficacy (hepatic metabolism induced)

• sebetralstat
Idhifa (enasidenib)

+

sebetralstat

1 interaction

Caution Advised

enasidenib + sebetralstat

caution advised: combo may decr. sebetralstat levels, efficacy (hepatic metabolism induced)

• seladelpar
Idhifa (enasidenib)

+

seladelpar

1 interaction

Caution Advised

enasidenib + seladelpar

caution advised: combo may incr. seladelpar levels, risk of adverse effects (BCRP-mediated transport inhibited, hepatic transport inhibited)

• selpercatinib
Idhifa (enasidenib)

+

selpercatinib

1 interaction

Caution Advised

enasidenib + selpercatinib

caution advised: combo may decr. selpercatinib levels, efficacy (hepatic metabolism induced)

• selumetinib
Idhifa (enasidenib)

+

selumetinib

1 interaction

Caution Advised

enasidenib + selumetinib

caution advised: combo may decr. selumetinib levels, efficacy (hepatic metabolism induced)

• sonidegib
Idhifa (enasidenib)

+

sonidegib

1 interaction

Caution Advised

enasidenib + sonidegib

caution advised: combo may decr. sonidegib levels, efficacy (hepatic metabolism induced)

• sulfasalazine
Idhifa (enasidenib)

+

sulfasalazine

1 interaction

Caution Advised

enasidenib + sulfasalazine

caution advised: combo may incr. sulfasalazine levels, risk of adverse effects; may decr. IBD tx efficacy (gut BCRP-mediated transport inhibited)

• suzetrigine
Idhifa (enasidenib)

+

suzetrigine

1 interaction

Caution Advised

enasidenib + suzetrigine

caution advised: combo may decr. suzetrigine and active metabolite levels, efficacy (hepatic metabolism induced)

• tadalafil
Idhifa (enasidenib)

+

tadalafil

1 interaction

Caution Advised

enasidenib + tadalafil

caution advised: combo may decr. tadalafil levels, efficacy (hepatic metabolism induced)

• taletrectinib
Idhifa (enasidenib)

+

taletrectinib

1 interaction

Caution Advised

enasidenib + taletrectinib

caution advised: combo may decr. taletrectinib levels, efficacy (hepatic metabolism induced)

• tamoxifen
Idhifa (enasidenib)

+

tamoxifen

1 interaction

Caution Advised

enasidenib + tamoxifen

caution advised: combo may decr. tamoxifen and active metabolite levels, efficacy (hepatic metabolism induced)

• tazemetostat
Idhifa (enasidenib)

+

tazemetostat

1 interaction

Caution Advised

enasidenib + tazemetostat

caution advised: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• temsirolimus
Idhifa (enasidenib)

+

temsirolimus

1 interaction

Caution Advised

enasidenib + temsirolimus

caution advised: combo may decr. temsirolimus and active metabolite sirolimus levels, efficacy (hepatic metabolism induced)

• tezacaftor/ivacaftor
Idhifa (enasidenib)

+

tezacaftor/ ivacaftor

1 interaction

Caution Advised

enasidenib + tezacaftor/ ivacaftor

caution advised: combo may decr. tezacaftor/ivacaftor levels, efficacy (hepatic metabolism induced)

• ticagrelor
Idhifa (enasidenib)

+

ticagrelor

1 interaction

Caution Advised

enasidenib + ticagrelor

caution advised: combo may decr. ticagrelor levels, efficacy (hepatic metabolism induced)

• tipranavir
Idhifa (enasidenib)

+

tipranavir

1 interaction

Caution Advised

enasidenib + tipranavir

caution advised: combo may decr. tipranavir levels, efficacy (hepatic metabolism induced)

• tofacitinib
Idhifa (enasidenib)

+

tofacitinib

1 interaction

Caution Advised

enasidenib + tofacitinib

caution advised: combo may decr. tofacitinib levels, efficacy (hepatic metabolism induced)

• tolvaptan
Idhifa (enasidenib)

+

tolvaptan

1 interaction

Caution Advised

enasidenib + tolvaptan

caution advised: combo may decr. tolvaptan levels, efficacy (hepatic metabolism induced)

• toremifene
Idhifa (enasidenib)

+

toremifene

1 interaction

Caution Advised

enasidenib + toremifene

caution advised: combo may decr. toremifene levels, efficacy (hepatic metabolism induced)

• vanzacaftor/tezacaftor/deutivacaftor
Idhifa (enasidenib)

+

vanzacaftor/ tezacaftor/ deutivacaftor

1 interaction

Caution Advised

enasidenib + vanzacaftor/ tezacaftor/ deutivacaftor

caution advised: combo may decr. vanzacaftor/tezacaftor/deutivacaftor levels, efficacy (hepatic metabolism induced)

• velpatasvir
Idhifa (enasidenib)

+

velpatasvir

1 interaction

Caution Advised

enasidenib + velpatasvir

caution advised: combo may decr. velpatasvir levels, efficacy (hepatic metabolism induced)

• verapamil
Idhifa (enasidenib)

+

verapamil

1 interaction

Caution Advised

enasidenib + verapamil

caution advised: combo may decr. verapamil levels, efficacy (hepatic metabolism induced)

• voclosporin
Idhifa (enasidenib)

+

voclosporin

1 interaction

Caution Advised

enasidenib + voclosporin

caution advised: combo may decr. voclosporin levels, efficacy (hepatic metabolism induced)

• vonoprazan
Idhifa (enasidenib)

+

vonoprazan

1 interaction

Caution Advised

enasidenib + vonoprazan

caution advised: combo may decr. vonoprazan levels, efficacy (hepatic metabolism induced)

• zanubrutinib
Idhifa (enasidenib)

+

zanubrutinib

1 interaction

Caution Advised

enasidenib + zanubrutinib

caution advised: combo may decr. zanubrutinib levels, efficacy (hepatic metabolism induced)

• ziftomenib
Idhifa (enasidenib)

+

ziftomenib

1 interaction

Caution Advised

enasidenib + ziftomenib

caution advised: combo may decr. ziftomenib levels, efficacy (hepatic metabolism induced)

• zolmitriptan
Idhifa (enasidenib)

+

zolmitriptan

1 interaction

Caution Advised

enasidenib + zolmitriptan

caution advised: combo may incr. zolmitriptan levels, risk of adverse effects (hepatic metabolism inhibited)

• zolpidem
Idhifa (enasidenib)

+

zolpidem

1 interaction

Caution Advised

enasidenib + zolpidem

caution advised: combo may incr. zolpidem levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)